SEC Filing Summary

This filing is a Form 4, reporting a transaction by Barrett Elizabeth A., a director at Allogene Therapeutics, Inc. On June 18, 2026, 95,400 Restricted Stock Units (RSUs) were awarded with a transaction value of $0.00. These RSUs represent a contingent right to receive one share of the Company's Common Stock per unit. The RSUs will vest in two equal semi-annual installments over one year, contingent upon continued service. The reporting person has elected to defer the receipt of Common Stock upon vesting until 30 days after separation from service or a change in control, as per the company's Non-Employee Director Compensation Policy. The shares were acquired under transaction code "A", indicating an acquisition.